12:00 AM
Mar 19, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ONT-10: Phase I started

Oncothyreon began a 2-part, U.S. Phase I trial to evaluate its ONT-10 given once weekly or every other week in patients with MUC1-expressing cancers, including breast, non-small cell...

Read the full 119 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >